Could live attenuated vaccines better control COVID-19?

Area of Science:

• Virology
• Vaccinology
• Immunology

Background:

• Current COVID-19 vaccines (mRNA, adenovirus, inactivated) face challenges like adverse effects, pre-existing immunity, and variant resistance.
• Existing vaccines may not provide broad protection against emerging SARS-CoV-2 variants.
• There is a need for novel vaccine strategies to overcome current limitations and enhance global pandemic control.

Purpose of the Study:

• To review existing SARS-CoV-2 vaccines, highlighting their advantages and disadvantages.
• To introduce novel temperature-sensitive SARS-CoV-2 variants as potential live-attenuated vaccine candidates.
• To discuss the optimization of vaccine strategies based on pandemic phases and efficacy.

Main Methods:

• Review of current literature on approved SARS-CoV-2 vaccines.
• Isolation and characterization of temperature-sensitive SARS-CoV-2 variants.
• Analysis of vaccine modalities, including live attenuated approaches.

Main Results:

• Identification of unique temperature-sensitive SARS-CoV-2 strains suitable for live attenuated vaccine development.
• Evaluation of the limitations of mRNA, adenovirus, and inactivated SARS-CoV-2 vaccines.
• Demonstration that live attenuated vaccines closely mimic natural infection without disease burden.

Conclusions:

• Novel temperature-sensitive SARS-CoV-2 variants present a viable option for live-attenuated vaccine development.
• Optimizing vaccine usage according to pandemic phase and efficacy is crucial for global recovery.
• Further research into these variants can enhance the COVID-19 vaccine repertoire.